Cadrenal Therapeutics, Inc. reported earnings results for the eleven months ended December 31, 2022. For the eleven months, the company reported net loss was USD 6.71 million. Basic loss per share from continuing operations was USD 0.85.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.46 USD | -5.23% | -6.22% | -37.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.83% | 7.36M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- CVKD Stock
- News Cadrenal Therapeutics, Inc.
- Cadrenal Therapeutics, Inc. Reports Earnings Results for the Eleven Months Ended December 31, 2022